Research
Metabolic adaptation
Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%).
Tirzepatide significantly reduces the risk of developing type 2 diabetes in individuals with obesity and prediabetes.
StrongSupportsmedium confidence
Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001).
Why this rating
Based on a large randomized controlled trial.
Source
Tirzepatide for Obesity Treatment and Diabetes Prevention
Ania M. Jastreboff et al. · New England Journal of Medicine · 2024
DOI 10.1056/nejmoa2410819
rct · n=2539Cited 359×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- At 176 weeks, the mean percent change in body weight among participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, compared with -1.3% among those who received placebo.Strong
- Three years of treatment with tirzepatide resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo.Strong
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →